Clinical and Experimental Hepatology
eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2025
vol. 11
 
Share:
Send email
Share:
abstract:
Review paper

Steatotic liver disease and chronic viral hepatitis

Jakub Janczura
1
,
Alessandra Mangia
2
,
Krystyna Dobrowolska
1
,
Michał Brzdęk
1
,
Kinga Brzdęk
1
,
Małgorzata Wajdowicz
3
,
Iwona Gorczyca-Głowacka
4
,
Piotr M. Stępień
5
,
Dorota Zarębska-Michaluk
5

  1. Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  2. Liver Unit, Fondazione “Casa Sollievo della Sofferenza”, IRCCS San Giovanni Rotondo, Rotondo, Italy
  3. Clinical Department of Infectious Diseases with Hepatology Subdivision, Collegium Medicum University of Rzeszow, Rzeszów, Poland
  4. Department of Psychiatry, Jan Kochanowski University, Kielce, Poland
  5. Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce, Poland
Clin Exp HEPATOL 2025; 11, 3: 219–227
DOI: https://doi.org/10.5114/ceh.2025.154220
Online publish date: 2025/09/22
View full text Get citation
 
PlumX metrics:
Steatotic liver disease (SLD) is a condition characterized by excessive fat accumulation within hepatocytes.

In recent years, the nomenclature and diagnostic framework of the disease have evolved and the term SLD has replaced the previous fatty liver disease classification. This change reflects a more inclusive understanding of the metabolic drivers of the disease and its strong association with systemic conditions. With the rising global prevalence of metabolic disorders, the burden of SLD has increased significantly, making it the leading cause of chronic liver disease worldwide. While many cases of SLD remain non-progressive, metabolic dysfunction associated steatohepatitis (MASH) may advance to fibrosis, cirrhosis, or hepatocellular carcinoma. The risk of disease progression may be greater when liver steatosis coexists with other hepatic insults, particularly chronic infections with hepatitis B virus or hepatitis C virus. This review explores the prevalence, interactions, and therapeutic implications of SLD in patients with chronic viral hepatitis.
keywords:

HBV, HCV, liver steatosis, chronic hepatitis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.